[HTML][HTML] Ras pathway inhibition prevents neovascularization by repressing endothelial cell sprouting

PD Westenskow, T Kurihara, E Aguilar… - The Journal of …, 2013 - Am Soc Clin Investig
PD Westenskow, T Kurihara, E Aguilar, EL Scheppke, SK Moreno, C Wittgrove, V Marchetti
The Journal of clinical investigation, 2013Am Soc Clin Investig
Vascular networks develop from a growing vascular front that responds to VEGF and other
guidance cues. Angiogenesis is required for normal tissue function, but, under conditions of
stress, inappropriate vascularization can lead to disease. Therefore, inhibition of angiogenic
sprouting may prevent neovascularization in patients with blinding neovascular eye
diseases, including macular degeneration. VEGF antagonists have therapeutic benefits but
also can elicit off-target effects. Here, we found that the Ras pathway, which functions …
Vascular networks develop from a growing vascular front that responds to VEGF and other guidance cues. Angiogenesis is required for normal tissue function, but, under conditions of stress, inappropriate vascularization can lead to disease. Therefore, inhibition of angiogenic sprouting may prevent neovascularization in patients with blinding neovascular eye diseases, including macular degeneration. VEGF antagonists have therapeutic benefits but also can elicit off-target effects. Here, we found that the Ras pathway, which functions downstream of a wide range of cytokines including VEGF, is active in the growing vascular front of developing and pathological vascular networks. The endogenous Ras inhibitor p120RasGAP was expressed predominately in quiescent VEGF-insensitive endothelial cells and was ectopically downregulated in multiple neovascular models. MicroRNA-132 negatively regulated p120RasGAP expression. Experimental delivery of α-miR-132 to developing mouse eyes disrupted tip cell Ras activity and prevented angiogenic sprouting. This strategy prevented ocular neovascularization in multiple rodent models even more potently than the VEGF antagonist, VEGF-trap. Targeting microRNA-132 as a therapeutic strategy may prove useful for treating multiple neovascular diseases of the eye and for preventing vision loss regardless of the neovascular stimulus.
The Journal of Clinical Investigation